Pergolide-associated valvular heart disease. 2006

E Andrew Waller, and Joseph Kaplan
Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32256, USA.

Pergolide is an ergot derivative dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. Ergot derivatives are known to be associated with fibrotic conditions, including a carcinoid-like, fibrotic, valvular heart disease (VHD). Recently, pergolide was identified in association with the development of VHD. This article includes a summary of the literature published on pergolide-associated VHD, a description of the potential mechanisms of drug-induced VHD, and the clinical implications for the management of patients taking pergolide.

UI MeSH Term Description Entries
D010479 Pergolide A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES. Celance,LY-127,809,LY-127809,Parkotil,Pergolide Mesylate,Permax,Pharken,LY127,809,LY127809,Mesylate, Pergolide
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006349 Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE). Heart Valvular Disease,Valvular Heart Diseases,Disease, Heart Valvular,Heart Disease, Valvular,Heart Valve Disease,Heart Valvular Diseases,Valve Disease, Heart,Valvular Disease, Heart,Valvular Heart Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012185 Retroperitoneal Fibrosis A slowly progressive condition of unknown etiology, characterized by deposition of fibrous tissue in the retroperitoneal space compressing the ureters, great vessels, bile duct, and other structures. When associated with abdominal aortic aneurysm, it may be called chronic periaortitis or inflammatory perianeurysmal fibrosis. Ormond Disease,Perianeurysmal Fibrosis, Inflammatory,Periaortitis, Chronic,Fibrosis, Inflammatory Perianeurysmal,Fibrosis, Perianeurysmal Inflammatory,Idiopathic Retroperitoneal Fibrosis,Inflammatory Fibrosis, Perianeurysmal,Inflammatory Perianeurysmal Fibrosis,Ormond's Disease,Perianeurysmal Inflammatory Fibrosis,Chronic Periaortitides,Chronic Periaortitis,Disease, Ormond,Disease, Ormond's,Fibroses, Retroperitoneal,Fibrosis, Retroperitoneal,Periaortitides, Chronic,Retroperitoneal Fibroses
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine

Related Publications

E Andrew Waller, and Joseph Kaplan
June 2003, Mayo Clinic proceedings,
E Andrew Waller, and Joseph Kaplan
January 2012, Acta medica academica,
E Andrew Waller, and Joseph Kaplan
December 2002, Mayo Clinic proceedings,
E Andrew Waller, and Joseph Kaplan
February 2006, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
E Andrew Waller, and Joseph Kaplan
November 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology,
E Andrew Waller, and Joseph Kaplan
November 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology,
E Andrew Waller, and Joseph Kaplan
December 2003, Prescrire international,
E Andrew Waller, and Joseph Kaplan
January 2007, ACP journal club,
Copied contents to your clipboard!